NAD+ for sale looks like a product page and behaves like a form. The honest listings fill in the same set of fields, the bad ones leave the same fields blank, and the gap between them is easier to read than any review.
Key takeaways
- Grade is the field that decides the rest. FDA has stated it is aware of compounders using food-grade NAD+ sold by repackagers to make intravenous products, which is a supply-chain problem rather than a vendor-reputation problem.
- Testing scope is a field, not a badge. Identity by mass spectrometry and purity by chromatography say the container holds NAD+; only a bacterial endotoxins result speaks to the contamination FDA connected to reported reactions.
- Quantity is stated in grams because NAD+ is not a peptide. A 1,000 mg presentation at $52.00 with the code is $5.20 per 100 mg, which is the unit that lets you compare anything.
- A lot number, a test date and a storage instruction are cheap to publish and awkward to fake convincingly. Their absence is the pattern worth walking away from.
- A listing that promises benefits is a listing that has already stepped outside the rules it sells under, and that tells you how it handles its other obligations.
The vendor we point lifters to
NAD+ from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 20, 2026.
NAD+ for sale: the fields that separate a listing from a storefront
Nine fields. Read them in this order, because the first two eliminate most of what a search returns.
| Field | What a real listing states | What an evasive listing does | Why it decides the purchase |
|---|---|---|---|
| Grade | A specification: pharmaceutical grade or equivalent | Says nothing at all, or says "high purity" instead | Food-grade material entering sterile preparations is the failure FDA named |
| Testing scope | Identity, purity and a bacterial endotoxins result | Shows a "third-party tested" badge with no document | Purity and endotoxin are different questions |
| Lot number | A batch number that matches the container label | Publishes one undated certificate for the whole catalog | Ties the document to the thing in the box |
| Test date | A date within a sensible window of the batch | Omits the date, or the date is years old | Tells you the certificate belongs to current stock |
| Laboratory | A named third-party laboratory | "Independent lab" with no name | A name can be searched, a phrase cannot |
| Quantity | Milligrams or grams stated plainly | Says "vial" and leaves you to guess | You cannot compute a unit price without it |
| Storage | A stated storage condition for the powder | Silent, or contradicts itself between pages | A gram sits with you for a long time |
| Use language | Explicit research-use-only wording | Human-use claims, protocols, before and after photos | A seller ignoring one rule set is a seller ignoring others |
| Seller identity | A business address, a phone number, terms | A contact form and nothing else | Recourse when an order goes wrong |
None of these are hard to publish. That is the point of using them as a filter: they cost an honest seller nothing and cost a dishonest one a lie that has to hold up.
The repackager problem, in the agency's own words
Most listing red flags are generic. This one is specific to NAD+, and it is the reason the grade field sits at the top of the table.
FDA published a notice reminding compounders to use ingredients suitable for sterile compounding, content current as of 10/30/2024. It states that the agency "is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products," and that "ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins, which can harm patients."
The notice then records what happened downstream: FDA "has received adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue with some requiring medical treatment," reactions the agency described as "consistent with excessive levels of endotoxins."
Two things follow for anyone reading a listing. First, the risk enters upstream, through material that was never intended for sterile use being relabeled and moved along a chain. A pleasant storefront and fast shipping do not touch that. Second, FDA in the same notice urged manufacturers and repackagers to "clearly identify any ingredients intended for use in foods or dietary supplements on the label," which is exactly the disclosure an evasive listing omits.
Testing scope is a field, not a badge
A "third-party tested" graphic is not a test result. What you want is a document, and what the document should contain is more than one kind of answer.
Identity by mass spectrometry says the material is nicotinamide adenine dinucleotide and not something else. Purity by chromatography says how much of the sample is that substance. Neither of them measures endotoxin, which is bacterial debris rather than a live organism, persists after the bacteria that produced it are gone, and requires its own compendial assay. FDA maintains a questions and answers guidance on pyrogen and endotoxins testing precisely because it is a separate discipline.
So the useful question to a seller is narrow and answerable: does the report for this lot include a bacterial endotoxins result. A seller with the document sends it. A seller without it usually changes the subject to purity, which is the answer to a different question.
Grams, not milligrams, and what that does to the price field
NAD+ is a coenzyme, not a peptide, and the quantities reflect that. Peptide listings on this site deal in 5 or 10 mg presentations. NAD+ listings deal in grams, which breaks the per-milligram habit: the same figure that reads as expensive for retatrutide reads as a rounding error here, and a per-milligram comparison across the two tells you nothing.
Quote it per 100 mg instead. A 1,000 mg presentation at $52.00 is $5.20 per 100 mg, and that unit is what makes two listings comparable at a glance. The full arithmetic, including what the quantity tiers do, is in NAD+ price, and the code itself in NAD+ coupon.
Searches for NAD+ vials for sale sometimes turn up listings quoting only a total price with no quantity anywhere on the page. That is not a bargain waiting to be discovered, it is a missing field.
Storage, and why a gram is a long relationship
A gram is not a week's purchase. Whatever the intended use, the container sits somewhere for months, which makes the storage field more consequential here than on a small peptide vial that is consumed quickly.
An honest listing states a storage condition for the lyophilised material and does not contradict itself between the product page, the FAQ and the packing slip. If a page is silent on storage, you are being asked to guess at the conditions that keep your own purchase intact. Handling after delivery, including what to check when the parcel lands, is covered in buy NAD+ online.
What "for sale" has to be attached to
Listings for NAD+ injection for sale are the ones to read hardest, because the phrasing points at a sterile finished product and research suppliers do not sell finished sterile drugs. Material sold as laboratory research material is exactly that, and the listing should say so without ambiguity.
The inverse is the clearest red flag in the market. A seller that advertises benefits, publishes protocols, or shows before and after photographs has stepped outside the rules the entire channel operates under. That is not a sign of confidence, it is a sign that the compliance obligations are being treated as optional, and the testing obligations sit in the same box. We applied the same reasoning to BPC-157 for sale and MOTS-c for sale; the difference here is that the regulator has already written about what happens when this particular chain fails.
For the domestic supply question specifically, including what "ships from the USA" is worth checking against, see NAD+ for sale USA.
Running the fields against a live listing
Ascension's NAD+ 1,000 mg listing fills most of the table. The quantity is stated, the price is $104.00 list and $52.00 with the code, which is $5.20 per 100 mg, and the page publishes two independent third-party reports for the batch, currently Kovera Labs batch 25-05260628 tested June 14, 2026 and MZ Biolabs batch 25-01260229 tested January 26, 2026. The listing carries research-use-only language, declines to discuss reconstitution or amounts, states same-day dispatch before 2pm CST, and lists free shipping over $250.
That is a documentation position read off the page rather than a laboratory verification we performed, and the remaining field is the one this whole article is about: if the published reports cover identity and purity without a bacterial endotoxins result, ask for it before ordering. Ask every seller the same thing, and treat a straight answer as worth more than a discount.
What a complete listing still cannot claim
Fill in all nine fields and you have confidence about the contents of a container. You do not have an outcome. NAD+ is central to energy metabolism, which is settled biochemistry, but the step from that to a better training week has not been closed by a finished human efficacy trial, and the registered trial record is the check on any listing that implies otherwise.
If the reason for reading this was a run of flat sessions, the boring candidates deserve to be ruled out first, in sleep and myostatin and, where an incretin drug is in the picture, myostatin inhibitors and GLP-1 muscle loss. A perfect listing does not change what the compound has been shown to do.
Frequently asked questions
What is the first thing to check on a NAD+ listing?
The grade of the material. FDA's compounding notice specifically describes food-grade NAD+ sold by repackagers being used to make intravenous products, so a listing that never states a grade has left the most consequential field blank.
Is "third-party tested" enough?
No. That phrase is a badge, not a document. Ask for the report for the lot you will receive, check that it names the laboratory and carries a test date, and check whether the testing scope goes beyond identity and purity to a bacterial endotoxins result.
Why do NAD+ listings sell grams when peptide listings sell milligrams?
Because NAD+ is a coenzyme rather than a peptide and is handled in far larger quantities. That is also why the sensible unit price is per 100 mg: a 1,000 mg presentation at $52.00 is $5.20 per 100 mg, while the same number per milligram invites a meaningless comparison against peptide pricing.
Are listings for NAD+ injections for sale legitimate?
Research suppliers sell laboratory material, not finished sterile injectable drugs, so a listing leaning on injection language is worth reading carefully. Sterile finished preparations come from compounding pharmacies against a prescription, which is a different route with different paperwork.
Does a low price by itself mean the material is bad?
Not by itself, but it is worth asking what was skipped to reach it. Grade, batch-specific testing, endotoxin assays and domestic dispatch all cost money, and the cheapest listings in this market are frequently the ones that omit exactly those fields.
This article is for educational purposes only and is not medical advice. NAD+ is a coenzyme rather than an approved injectable medicine: there is no FDA-approved NAD+ drug product, material sold by research suppliers is labeled for laboratory use only and not for human consumption, and compounded preparations exist under a stated enforcement policy rather than an approval. Speak with a qualified healthcare professional before making any decision involving injections, infusions or off-label compounds.